{"id":11290,"date":"2023-11-21T21:36:00","date_gmt":"2023-11-21T13:36:00","guid":{"rendered":"https:\/\/flcube.com\/?p=11290"},"modified":"2024-11-04T21:42:16","modified_gmt":"2024-11-04T13:42:16","slug":"chiesi-farmaceutici-acquires-global-rights-to-haisco-pharmaceuticals-hsk31858-for-respiratory-diseases","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=11290","title":{"rendered":"Chiesi Farmaceutici Acquires Global Rights to Haisco Pharmaceutical’s HSK31858 for Respiratory Diseases"},"content":{"rendered":"\n

Italy-based Chiesi Farmaceutici S.p.A has announced a licensing agreement with China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653<\/a>), acquiring rights to the latter’s reversible dipeptidyl peptidase 1 (DPP1) inhibitor, HSK31858, for respiratory diseases. Chiesi will assume development, manufacturing, and commercial rights to the molecule in markets outside Greater China, excluding China mainland, Hong Kong, Macau, and Taiwan. An upfront fee of USD 13 million will be paid to Haisco, with Chiesi committing to milestone payments totaling up to USD 462 million. Royalties on future sales will also be paid by Chiesi, though specific details remain undisclosed.<\/p>\n\n\n\n

HSK31858: A Potential Anti-Inflammatory for Respiratory Diseases<\/strong><\/p>\n\n\n\n

HSK31858 is an oral, potent, and highly selective small-molecule DPP1 inhibitor currently in the Phase II stage of development in China as an anti-inflammatory agent for bronchiectasis. Bronchiectasis is a long-term condition characterized by the widening of the airways in the lungs, leading to a build-up of excess mucus and increased vulnerability to infection. Respiratory disease is one of Chiesi’s core therapeutic areas, and this deal is seen as a strategic expansion of its presence in the field.- Flcube.com<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Italy-based Chiesi Farmaceutici S.p.A has announced a licensing agreement with China-based Haisco Pharmaceutical Group Co.,…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[1919,139,929],"class_list":["post-11290","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-chiesi-farmaceutici","tag-haisco-pharmaceutical","tag-she-002653"],"yoast_head":"\nChiesi Farmaceutici Acquires Global Rights to Haisco Pharmaceutical's HSK31858 for Respiratory Diseases - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Italy-based Chiesi Farmaceutici S.p.A has announced a licensing agreement with China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653), acquiring rights to the latter's reversible dipeptidyl peptidase 1 (DPP1) inhibitor, HSK31858, for respiratory diseases. Chiesi will assume development, manufacturing, and commercial rights to the molecule in markets outside Greater China, excluding China mainland, Hong Kong, Macau, and Taiwan. An upfront fee of USD 13 million will be paid to Haisco, with Chiesi committing to milestone payments totaling up to USD 462 million. Royalties on future sales will also be paid by Chiesi, though specific details remain undisclosed.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=11290\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Chiesi Farmaceutici Acquires Global Rights to Haisco Pharmaceutical's HSK31858 for Respiratory Diseases\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=11290\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-11-21T13:36:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-04T13:42:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11290#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11290\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Chiesi Farmaceutici Acquires Global Rights to Haisco Pharmaceutical’s HSK31858 for Respiratory Diseases\",\"datePublished\":\"2023-11-21T13:36:00+00:00\",\"dateModified\":\"2024-11-04T13:42:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11290\"},\"wordCount\":197,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Chiesi Farmaceutici\",\"Haisco Pharmaceutical\",\"SHE: 002653\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=11290#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11290\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=11290\",\"name\":\"Chiesi Farmaceutici Acquires Global Rights to Haisco Pharmaceutical's HSK31858 for Respiratory Diseases - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-11-21T13:36:00+00:00\",\"dateModified\":\"2024-11-04T13:42:16+00:00\",\"description\":\"Italy-based Chiesi Farmaceutici S.p.A has announced a licensing agreement with China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653), acquiring rights to the latter's reversible dipeptidyl peptidase 1 (DPP1) inhibitor, HSK31858, for respiratory diseases. Chiesi will assume development, manufacturing, and commercial rights to the molecule in markets outside Greater China, excluding China mainland, Hong Kong, Macau, and Taiwan. An upfront fee of USD 13 million will be paid to Haisco, with Chiesi committing to milestone payments totaling up to USD 462 million. Royalties on future sales will also be paid by Chiesi, though specific details remain undisclosed.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11290#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=11290\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=11290#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Chiesi Farmaceutici Acquires Global Rights to Haisco Pharmaceutical’s HSK31858 for Respiratory Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Chiesi Farmaceutici Acquires Global Rights to Haisco Pharmaceutical's HSK31858 for Respiratory Diseases - Insight, China's Pharmaceutical Industry","description":"Italy-based Chiesi Farmaceutici S.p.A has announced a licensing agreement with China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653), acquiring rights to the latter's reversible dipeptidyl peptidase 1 (DPP1) inhibitor, HSK31858, for respiratory diseases. Chiesi will assume development, manufacturing, and commercial rights to the molecule in markets outside Greater China, excluding China mainland, Hong Kong, Macau, and Taiwan. An upfront fee of USD 13 million will be paid to Haisco, with Chiesi committing to milestone payments totaling up to USD 462 million. Royalties on future sales will also be paid by Chiesi, though specific details remain undisclosed.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=11290","og_locale":"en_US","og_type":"article","og_title":"Chiesi Farmaceutici Acquires Global Rights to Haisco Pharmaceutical's HSK31858 for Respiratory Diseases","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=11290","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-11-21T13:36:00+00:00","article_modified_time":"2024-11-04T13:42:16+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=11290#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=11290"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Chiesi Farmaceutici Acquires Global Rights to Haisco Pharmaceutical’s HSK31858 for Respiratory Diseases","datePublished":"2023-11-21T13:36:00+00:00","dateModified":"2024-11-04T13:42:16+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=11290"},"wordCount":197,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Chiesi Farmaceutici","Haisco Pharmaceutical","SHE: 002653"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=11290#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=11290","url":"https:\/\/flcube.com\/?p=11290","name":"Chiesi Farmaceutici Acquires Global Rights to Haisco Pharmaceutical's HSK31858 for Respiratory Diseases - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-11-21T13:36:00+00:00","dateModified":"2024-11-04T13:42:16+00:00","description":"Italy-based Chiesi Farmaceutici S.p.A has announced a licensing agreement with China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653), acquiring rights to the latter's reversible dipeptidyl peptidase 1 (DPP1) inhibitor, HSK31858, for respiratory diseases. Chiesi will assume development, manufacturing, and commercial rights to the molecule in markets outside Greater China, excluding China mainland, Hong Kong, Macau, and Taiwan. An upfront fee of USD 13 million will be paid to Haisco, with Chiesi committing to milestone payments totaling up to USD 462 million. Royalties on future sales will also be paid by Chiesi, though specific details remain undisclosed.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=11290#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=11290"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=11290#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Chiesi Farmaceutici Acquires Global Rights to Haisco Pharmaceutical’s HSK31858 for Respiratory Diseases"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/11290","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=11290"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/11290\/revisions"}],"predecessor-version":[{"id":11292,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/11290\/revisions\/11292"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=11290"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=11290"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=11290"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}